Gilead Sciences and Lakefront Biotherapeutics closed the acquisition of Ouro Medicines on June 4, 2026, expanding Lakefront's inflammation pipeline.1 Lakefront, formerly Galapagos, is also co-developing gamgertamig with Gilead — a second front in its strategic repositioning.
Under deal terms, Lakefront can deploy at least $500 million of available cash independently of Gilead and outside the Ouro transaction framework.1 Up to $150 million of that sum is earmarked for share buybacks.1 The structure preserves Lakefront's ability to pursue further independent acquisitions without Gilead's involvement.
The Ouro portfolio will form the basis of Lakefront's R&D pipeline going forward.1 That gives Lakefront two simultaneous growth tracks: a co-development partnership with Gilead and a self-directed pipeline anchored in Ouro's inflammation assets.
The deal lands inside a wider consolidation cycle accelerating across biotech. JAKAFI's 2028 patent cliff is creating urgency among incumbents seeking replacement revenue. Acquirers are moving earlier into pipelines, buying platforms ahead of Phase 3 data rather than waiting for de-risked assets.
Clinical momentum at EHA 2026 is reinforcing the logic. T-cell engagers, in vivo CAR-T platforms, and JAK2 inhibitors are generating Phase 2/3 readouts, signaling these modalities are approaching commercial viability. An FDA PDUFA date for ifinatamab deruxtecan is set for October 2026. Awiqli is approaching U.S. launch — further compressing the window between pipeline investment and commercial return.
Nanobiotix's CONVERGE trial offers a reference point for next-gen efficacy gains. The program reported a 57.1% complete response rate (4 of 7 patients) in Stage 3 Inoperable NSCLC at ESTRO 2026.2 The current standard of care — concurrent chemoradiation with or without durvalumab — achieves complete responses in fewer than 5% of patients.2
VERAXA Biotech is building discovery infrastructure across bispecific T-cell engagers and bispecific antibody-drug conjugates, applying quality-by-design principles to next-generation antibody formats.3 The platform reflects broader industry investment in multi-specific modalities as the successor to approved checkpoint inhibitors.
